Enveda Biosciences logo

Enveda Biosciences

Emerging

Enveda Biosciences uses AI, metabolomics, and robotics to mine natural products for novel drug candidates; platform identifies chemical structure and activity from complex biological samples; raised $51M Series B in 2023;

Best for: Natural Product Drug Discovery — AI & Metabolomics PlatformEmerging, rapid growth
Life Sciences & BioTechNatural Product Drug Discovery — AI & Metabolomics PlatformWebsiteUpdated May 2026

Company Overview

About Enveda Biosciences

Enveda Biosciences is a drug discovery company founded in 2020 and headquartered in Boulder, Colorado, that is revitalizing natural product chemistry as a source of novel pharmaceutical compounds using modern AI and metabolomics. Natural products — molecules produced by plants, fungi, bacteria, and other organisms — have historically been the origin of over 60% of approved drugs, including penicillin, aspirin, morphine, and paclitaxel. However, traditional natural product discovery was slow, requiring isolation and purification of individual compounds from complex biological mixtures before testing. Enveda's platform eliminates this bottleneck by using mass spectrometry, machine learning, and robotics to identify the chemical structure, biological activity, and function of molecules directly from complex natural samples — without requiring isolation of individual compounds first.

Business Model & Competitive Advantage

Enveda's platform ingests data from thousands of natural samples, maps the chemical space of each using metabolomics and MS/MS fragmentation data, and applies AI models to predict molecular structure, prioritize candidates by predicted biological activity, and identify which molecules are most likely to become tractable drug leads. The company raised a $51M Series B in 2023 led by Kinnevik and The Engine (MIT's deep tech fund), with previous participation from investors including Khosla Ventures. Enveda's therapeutic pipeline targets infectious diseases and neurological conditions — areas with high unmet need and historical precedent for natural product-derived drugs.

Competitive Landscape 2025–2026

Enveda operates in the intersection of AI drug discovery and natural product chemistry — a combination that addresses one of the industry's most neglected sources of chemical novelty. While AI drug discovery has attracted billions in investment targeting known protein targets with synthetic compounds, Enveda's approach opens access to a largely unexplored chemical universe with billions of structurally diverse natural compounds — many of which have been shaped by billions of years of evolutionary pressure to interact with biological targets.

Founded
2020
Headquarters
Boulder, Colorado
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Enveda Biosciences is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.

Frequently Asked Questions

Similar Brands

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

For Enveda Biosciences

Claim This Profile

Are you from Enveda Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Enveda Biosciences Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Enveda Biosciences vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →